Browse by Phase
Phase 2 Clinical Trials
Phase 2 trials study whether a drug works in people with a specific disease or condition. These studies enroll 100–300 participants and also continue to evaluate safety.
Total Trials
1,083
Recruiting Now
1,083
Top Conditions in Phase 2
Frequently Asked Questions — Phase 2 Trials
What does a Phase 2 clinical trial evaluate?
Phase 2 trials assess whether a drug or treatment works in people with a specific disease or condition. Enrolling 100–300 participants, these studies collect preliminary efficacy data while continuing to monitor safety and identify the optimal dosing regimen. A successful Phase 2 outcome is required to advance to large-scale Phase 3 testing.
How long do Phase 2 trials typically take?
Phase 2 clinical trials typically run for 1–4 years, depending on the condition, endpoint complexity, and enrollment rate. Rare disease trials or those with long-term outcome measures may run longer. Many sponsors run Phase 2 studies at multiple sites simultaneously to accelerate recruitment.
Who can participate in a Phase 2 clinical trial?
Eligibility for Phase 2 trials is defined by specific inclusion and exclusion criteria. Participants are typically patients diagnosed with the condition under study and may or may not have received prior treatment. Age, disease stage, comorbidities, and laboratory values are common eligibility factors. Review each trial's criteria on ClinicalTrials.gov for specific requirements.
Active Phase 2 Studies
NCT07229417 Phase 2
Recruiting
A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractor...
Condition
Metastatic Endocrine Refractory
Enrollment
29 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT06119789 Phase 2
Recruiting
Precision Cancer Therapy in Rare Cancers
Condition
Rare Malignant Neoplasm
Enrollment
96 pts
Location
Norway
Sponsor
Oslo University Hospital
NCT07014410 Phase 2
Recruiting
Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and H...
Condition
Breast Cancer
Enrollment
63 pts
Location
China
Sponsor
Zhejiang Cancer Hospital
NCT05777824 Phase 2
Recruiting
Postoperative Management for HNSCC Based on Pathological Response of Induction C...
Condition
Head and Neck Cancer
Enrollment
84 pts
Location
China
Sponsor
Cancer Institute and Hospital,
NCT05932680 Phase 2
Recruiting
Limited-duration Teclistamab
Condition
Myeloma Multiple
Enrollment
75 pts
Location
United States
Sponsor
Abramson Cancer Center at Penn
NCT06019468 Phase 2
Recruiting
Neoadjuvant Treatment For Locally Advanced Thymic Cancer
Condition
Thymic Carcinoma
Enrollment
25 pts
Location
China
Sponsor
Shanghai Pulmonary Hospital, S
NCT07522879 Phase 2
Recruiting
A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Th...
Condition
Adenoid Cystic Carcinoma
Enrollment
40 pts
Location
China
Sponsor
Eye & ENT Hospital of Fudan Un
NCT06241846 Phase 2
Recruiting
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201...
Condition
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment
100 pts
Location
China
Sponsor
MediLink Therapeutics (Suzhou)
NCT06034561 Phase 2
Recruiting
Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia
Condition
Acute Lymphoblastic Leukemia, in Relapse
Enrollment
50 pts
Location
Brazil
Sponsor
Instituto do Cancer do Estado
NCT06824883 Phase 2
Recruiting
Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma
Condition
Extranodal NK/T-cell Lymphoma
Enrollment
49 pts
Location
China
Sponsor
Peking Union Medical College H
NCT06794541 Phase 2
Recruiting
A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Pat...
Condition
Complicated Intra-abdominal Infections (cIAI)
Enrollment
35 pts
Location
United States
Sponsor
Tetraphase Pharmaceuticals, In
NCT06865339 Phase 2
Recruiting
Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-...
Condition
NSCLC
Enrollment
76 pts
Location
United States
Sponsor
Montefiore Medical Center
NCT05796375 Phase 2
Recruiting
Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder...
Condition
Non-muscle-invasive Bladder Cancer
Enrollment
240 pts
Location
United States
Sponsor
White River Junction Veterans
NCT06758700 Phase 2
Recruiting
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell ...
Condition
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Enrollment
15 pts
Location
China
Sponsor
Shanghai Pulmonary Hospital, S
NCT06605664 Phase 2
Recruiting
Hyperpolarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Radi...
Condition
Hepatocellular Carcinoma (HCC)
Enrollment
45 pts
Location
Taiwan
Sponsor
Chang Gung Memorial Hospital
NCT05636787 Phase 2
Recruiting
Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi®...
Condition
Multiple Myeloma
Enrollment
120 pts
Location
Switzerland
Sponsor
Insel Gruppe AG, University Ho
NCT06383884 Phase 2
Recruiting
Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion
Condition
Solid Tumor, Adult
Enrollment
30 pts
Location
South Korea
Sponsor
Samsung Medical Center
NCT07441200 Phase 2
Recruiting
Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (P...
Condition
Pulmonary Arterial Hypertension
Enrollment
135 pts
Location
Japan
Sponsor
NS Pharma, Inc.
NCT07002216 Phase 2
Recruiting
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
Condition
Hodgkin Lymphoma
Enrollment
48 pts
Location
United States
Sponsor
University of Miami
NCT07296705 Phase 2
Recruiting
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Pres...
Condition
Muscle Invasive Bladder Cancer (MIBC)
Enrollment
25 pts
Location
China
Sponsor
Fujian Medical University Unio
NCT07766005 Phase 2
Recruiting
A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (Th...
Condition
Hidradenitis Suppurativa (HS)
Enrollment
150 pts
Location
United States, Canada
Sponsor
Spyre Therapeutics, Inc.
NCT06458439 Phase 2
Recruiting
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
Condition
Lymphoma, Non-Hodgkin
Enrollment
31 pts
Location
United States
Sponsor
Abramson Cancer Center at Penn
NCT05657639 Phase 2
Recruiting
CAV Regimen for R/R AML
Condition
Acute Myeloid Leukemia
Enrollment
68 pts
Location
China
Sponsor
The First Affiliated Hospital
NCT06517511 Phase 2
Recruiting
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated ...
Condition
Diffuse Large B Cell Lymphoma
Enrollment
42 pts
Location
China
Sponsor
Sun Yat-sen University
NCT07602049 Phase 2
Recruiting
Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma
Condition
Soft Tissue Sarcoma (STS)
Enrollment
57 pts
Location
China
Sponsor
Sun Yat-sen University
Page 1 of 44 — 1,083 trials total
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology